UTHR:NGS-United Therapeutics Corporation (USD)

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing

USD 319.86

Change

+6.87 (+2.19)%

Market Cap

USD 5.48B

Volume

0.38M

Analyst Target

USD 144.78
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

United Therapeutics Corp is a biotechnology company. The Company is engaged in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-03-24 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

-2.70 (-0.53%)

USD 123.21B
REGN Regeneron Pharmaceuticals Inc

-26.86 (-4.06%)

USD 76.39B
ARGX argenx NV ADR

-2.43 (-0.40%)

USD 37.97B
ALNY Alnylam Pharmaceuticals Inc

-9.74 (-3.35%)

USD 31.94B
ONC BeiGene, Ltd.

-2.73 (-1.08%)

USD 28.70B
RPRX Royalty Pharma Plc

+0.01 (+0.03%)

USD 19.31B
SMMT Summit Therapeutics PLC

-0.45 (-2.17%)

USD 14.57B
INCY Incyte Corporation

-0.70 (-1.12%)

USD 14.22B
MRNA Moderna Inc

-0.32 (-0.94%)

USD 13.74B
INSM Insmed Inc

-0.84 (-1.06%)

USD 13.70B

ETFs Containing UTHR

MUUSAS:SW UBS (Irl) Fund Solutions .. 195.50 % 0.00 %

N/A

USD 0.47B
SANE 4.17 % 0.00 %

N/A

N/A
BIOT:SW L&G Pharma Breakthrough U.. 3.36 % 0.00 %

+0.05 (+-2.12%)

N/A
SRHQ Elevation Series Trust - .. 2.36 % 0.00 %

-0.06 (-2.12%)

N/A
WBIO:LSE WisdomTree BioRevolution .. 1.98 % 0.00 %

-17.40 (-2.12%)

USD 4.20M
WDNA WisdomTree BioRevolution .. 1.84 % 0.00 %

-0.29 (-2.12%)

USD 2.22M
WRNA:XETRA WisdomTree BioRevolution .. 1.84 % 0.00 %

-0.20 (-2.12%)

USD 2.77M
DSMC ETF Series Solutions 1.77 % 0.00 %

-0.13 (-2.12%)

N/A
THNZ:XETRA 0.85 % 0.00 %

N/A

N/A
IQSM Iq Candriam ESG U.S. Mid .. 0.82 % 0.00 %

-0.11 (-2.12%)

N/A
JMEE JPMorgan Market Expansion.. 0.61 % 0.00 %

-0.17 (-2.12%)

USD 1.69B
FBT First Trust NYSE Arca Bio.. 0.00 % 0.57 %

-2.19 (-2.12%)

N/A
GURU Global X Guru Index ETF 0.00 % 0.75 %

-0.12 (-2.12%)

N/A
LABD Direxion Daily S&P Biotec.. 0.00 % 1.00 %

+0.37 (+-2.12%)

USD 0.05B
LABU Direxion Daily S&P Biotec.. 0.00 % 1.14 %

-4.61 (-2.12%)

USD 0.66B
PJP Invesco Dynamic Pharmaceu.. 0.00 % 0.56 %

-1.63 (-2.12%)

N/A
BIGT:LSE L&G Pharma Breakthrough U.. 0.00 % 0.00 %

-6.15 (-2.12%)

N/A
BIOT:LSE L&G PHARMA BREAKTHROUGH G.. 0.00 % 0.00 %

-0.02 (-2.12%)

N/A
XBI SPDR® S&P Biotech ETF 0.00 % 0.35 %

-1.74 (-2.12%)

N/A
ETLI:F Legal & General UCITS ETF.. 0.00 % 0.00 %

+0.10 (+-2.12%)

N/A
IS3T:F iShares IV Public Limited.. 0.00 % 0.00 %

+0.22 (+-2.12%)

N/A
QDVC:F iShares IV Public Limited.. 0.00 % 0.00 %

+0.19 (+-2.12%)

N/A
BIOT 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -9.35% 58% F 38% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -9.35% 58% F 38% F
Trailing 12 Months  
Capital Gain 30.95% 85% B 83% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 30.95% 85% B 83% B
Trailing 5 Years  
Capital Gain 253.28% 91% A- 89% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 253.28% 91% A- 89% A-
Average Annual (5 Year Horizon)  
Capital Gain 27.24% 70% C- 80% B-
Dividend Return 27.24% 70% C- 79% B-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 31.13% 84% B 59% D-
Risk Adjusted Return 87.51% 100% F 93% A
Market Capitalization 5.48B 99% N/A 95% A

Key Financial Ratios

  Ratio vs. Industry/Classification (Biotechnology) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 8.80 38% 63%
Price/Book Ratio 2.23 47% 44%
Price / Cash Flow Ratio 10.83 4% 27%
Price/Free Cash Flow Ratio 6.90 8% 43%
Management Effectiveness  
Return on Equity 19.23% 96% 89%
Return on Invested Capital 15.39% 85% 81%
Return on Assets 12.44% 98% 97%
Debt to Equity Ratio N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.